Contact Us
Drug Search Results
More Filters [+]

Rasagiline

Alternative Names: rasagiline, azilect, tvp-1012, HNC364, HNC-364, HNC 364, rasagilintartrat, rasagilin
Latest Update: 2024-09-27
Latest Update Note: Clinical Trial Update

Product Description

Rasagiline (Azilect(®)) is an oral, second-generation, selective, irreversible monoamine oxidase-B (MAO-B) inhibitor approved in the US for the treatment of Parkinson's disease.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25322951/)

Mechanisms of Action: MAO-b Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Netherlands | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rasagiline

Countries in Clinic: China, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
HNC364-A101

P1

Completed

Parkinson's Disease

2024-04-15

CTR20231500

P1

Recruiting

Parkinson's Disease

None

Recent News Events

Date

Type

Title

09/04/2024

News Article

 Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

07/22/2024

News Article

 Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

09/26/2023

News Article

 Inlet Separation Device Market 2023 Demand, Growth, Research Report 2031

09/25/2023

News Article

 [2023-2031] Surgical N95 Respirators Market Insights Report

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions